The U.S. Food and Drug Administration has approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time gene therapy from Ultragenyx Pharmaceutical, as the first-ever approved treatment for Sanfilippo syndrome Type A, a rare and fatal inherited disease that progressively destroys children’s cognitive and neurological function. Until this approval, families facing the diagnosis had access only to treatments that managed symptoms, with nothing available to change the underlying course of the disease itself.
What Sanfilippo Syndrome Type A Does to Children
Sanfilippo syndrome Type A, also known as mucopolysaccharidosis type IIIA or MPS IIIA, is a rare inherited disorder that progressively damages the brain and nervous system. Children affected by the condition typically develop normally in their earliest years before entering a relentless regression, gradually losing cognitive, language, and other developmental abilities they had already gained.
“Children who develop normally in their earliest years face a relentless regression with no approved treatment to slow it.”
— Karim Mikhail, Director, FDA Center for Biologics Evaluation and Research
How Fayuvi Works
Fayuvi is administered as a single intravenous infusion, using a modified, non-infectious virus known as an adeno-associated virus serotype 9, or AAV9, to deliver a working copy of the SGSH gene into a patient’s cells. That gene enables the body to produce sulfamidase, the enzyme that is missing or deficient in children with MPS IIIA. Without functioning sulfamidase, a substance called heparan sulfate builds up progressively throughout the body and brain; restoring the enzyme’s function allows that buildup to be properly broken down instead, addressing the disease’s underlying biological cause rather than only managing its symptoms.
The Clinical Evidence Behind the Approval
Fayuvi’s safety and effectiveness were evaluated in an open-label, single-arm, multicenter clinical study of pediatric patients with MPS IIIA, measuring mean changes in cognitive scores among children between two and five years old. Treated patients maintained or improved cognitive function compared with an untreated historical control cohort, a meaningful divergence from the plateau-and-decline pattern the disease typically follows during that critical developmental window.
It’s worth being clear about what that trial design does and doesn’t establish. Because the study was open-label and single-arm, comparing outcomes against a historical control group rather than a concurrently randomized placebo arm, the evidence, while considered compelling enough by FDA reviewers to support approval, reflects a different and generally less rigorous standard of comparison than a traditional randomized controlled trial. Megha Kaushal, Acting Deputy Director of the FDA’s Office of Therapeutic Products, called the result a significant scientific milestone, demonstrating that a single intravenous gene therapy infusion can deliver therapeutically relevant effects to the central nervous system in pediatric patients.
Safety Considerations
Like other AAV-based gene therapies, Fayuvi carries meaningful safety considerations that patients and families need to weigh alongside its benefits. The most common adverse reactions reported in more than 5 percent of patients included elevated liver enzymes, nausea and vomiting, fever, decreased appetite, reduced white blood cell and platelet counts, and increased amylase levels. The FDA has flagged an important safety warning for thrombotic microangiopathy, a serious blood vessel disorder, and noted a potential long-term risk that the therapy’s inserted genetic material could integrate into a patient’s genome in a way that might eventually contribute to tumor development, a theoretical risk associated with this class of gene therapy more broadly.
Because of these risks, Fayuvi must be administered in a healthcare setting equipped to manage infusion reactions, and all patients receive corticosteroid treatment starting one day before the infusion and continuing for a minimum of eight weeks afterward to help manage the body’s immune response to the therapy.
What This Means for Ultragenyx and the Rare Disease Field
The approval marks Ultragenyx’s second gene therapy approval and sixth FDA approval overall, and the company received a Priority Review Voucher as part of the decision, a designation the FDA awards for rare pediatric disease treatments that can be used to expedite review of a future drug application. Ultragenyx’s UltraCare program will support patient access, with the company saying commercial product is expected to be available to ship to Qualified Treatment Centers within 30 to 60 days of approval.
“This is a historic milestone for a community that has waited far too long, but has never given up hope.”
— Emil D. Kakkis, CEO, Ultragenyx Pharmaceutical
What Comes Next
Access, rather than the science itself, will likely determine how quickly this approval translates into real-world impact. Gene therapies for ultra-rare conditions typically carry steep price tags and require coordination between specialized treatment centers and insurers before families can actually receive them, a logistical and financial hurdle that often lags well behind an approval announcement. For now, the FDA’s decision gives families facing a Sanfilippo Type A diagnosis something that, until this week, did not exist: an approved treatment aimed at changing the disease’s course rather than only managing its symptoms.
This article is for general informational purposes and does not constitute medical advice. Families considering treatment for Sanfilippo syndrome Type A should discuss all available options with their child’s physician.